M&A Deal Summary

Cubist Pharmaceuticals Acquires Adolor

On December 12, 2011, Cubist Pharmaceuticals acquired life science company Adolor for 453M USD

Acquisition Highlights
  • This is Cubist Pharmaceuticals’ 3rd transaction in the Life Science sector.
  • This is Cubist Pharmaceuticals’ 3rd largest (disclosed) transaction.
  • This is Cubist Pharmaceuticals’ 3rd transaction in the United States.
  • This is Cubist Pharmaceuticals’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2011-12-12
Target Adolor
Sector Life Science
Buyer(s) Cubist Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 453M USD
Advisor(s) Stifel, Nicolaus & Co., Inc. (Financial)
Dechert (Legal)

Target

Adolor

Exton, Pennsylvania, United States
Adolor Corp is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cubist Pharmaceuticals

Lexington, Massachusetts, United States
Category Company
Founded 1992
Sector Life Science
Employees900
Revenue 1.1B USD (2013)
DESCRIPTION

Cubist Pharmaceuticals, Inc. is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

DEAL STATS #
Overall 3 of 5
Sector (Life Science) 3 of 5
Type (Add-on Acquisition) 3 of 5
State (Pennsylvania) 1 of 1
Country (United States) 3 of 5
Year (2011) 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-12-14 Calixa Therapeutics

San Diego, California, United States

Calixa Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-07-30 Trius Therapeutics

San Diego, California, United States

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Buy $707M
Mergr

Product

Company

Legal